Scarica l'app Stockscreener
55.50
3.04%
-1.74
Dopo l'orario di chiusura:
55.50
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
Perpetual Ltd Grows Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history - Yahoo Finance Australia
Here Is Why BioMarin (BMRN) Is Projected to Rally - MSN
BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
BMRN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BioMarin Pharmaceutical (BMRN) receives FDA approval for expanded use of PALYNZIQ in adolescents - MSN
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
BioMarin at TD Cowen Conference: Strategic Growth Amid Challenges - Investing.com
BioMarin Pharmaceutical Inc. (BMRN) rated overweight at Wells Fargo despite Voxzogo phase 2 study discontinuations - MSN
Here is Why BioMarin (BMRN) is Projected to Rally - Insider Monkey
What BioMarin Pharmaceutical (BMRN)'s Voxzogo Trial Stops and Mixed Safety Data Mean For Shareholders - Sahm
BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations - Insider Monkey
5 Quality Value Stocks Likely to Make a Comeback According to Analysts - Insider Monkey
BMRN SEC FilingsBiomarin Pharmaceutical Inc 10-K, 10-Q, 8-K Forms - Stock Titan
(BMRN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Exploring High Growth Tech Stocks In The US Market March 2026 - simplywall.st
Vanguard disaggregates holdings; BioMarin (NASDAQ: BMRN) shows 0 shares reported - Stock Titan
BioMarin Bests Ascendis in Appeal Over Patent Suit Stay (1) - Bloomberg Law News
BioMarin Pharmaceutical (NASDAQ:BMRN) Rating Increased to Strong-Buy at Truist Financial - marketbeat.com
BioMarin (BMRN) down 13.6% since last earnings report: Can it rebound? - MSN
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Assenagon Asset Management S.A. Raises Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Swiss Life Asset Management Ltd Sells 54,282 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin shares drop 4% as Voxzogo trials are discontinued - MSN
RNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - The Motley Fool
BioMarin Pharmaceutical (BMRN) reports positive results from ongoing trials of VOXZOGO - msn.com
Top 3 Health Care Stocks That Are Set To Fly In March - Benzinga
BioMarin (BMRN) legal chief has 1,273 shares withheld for taxes - Stock Titan
BioMarin (BMRN) CTO reports 1,693-share tax withholding, holds 84,140 - Stock Titan
BioMarin (NASDAQ: BMRN) CFO has 2,117 shares withheld for tax - Stock Titan
BioMarin (BMRN) CEO reports tax-withholding share disposition - Stock Titan
Hudson Bay Capital Management LP Increases Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin (BMRN) EVP Hubbard receives stock awards and withholds shares for tax - Stock Titan
BioMarin (NASDAQ: BMRN) EVP granted stock, options and covers tax with shares - Stock Titan
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease - TipRanks
BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
What Does Wall Street Think About BioMarin Pharmaceutical (BMRN)? - MSN
[Form 4] BIOMARIN PHARMACEUTICAL INC In... - Stock Titan
BioMarin (NASDAQ: BMRN) CFO gets stock grants and tax share withholding - Stock Titan
BioMarin (BMRN) CEO granted 89,200 options and 62,440 RSUs in 2026 awards - Stock Titan
Price-Driven Insight from (BMRN) for Rule-Based Strategy - Stock Traders Daily
A Look At BioMarin Pharmaceutical (BMRN) Valuation After A Year Of Softer Share Price Momentum - Sahm
Wolfe Research Maintains Outperform on BioMarin (BMRN) March 16, 2026 - Meyka
BioMarin Pharmaceutical Inc. 8-K Filing: Company Information, Address, and Stock Details (March 16, 2026) - Minichart
Cantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN) - MSN
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap DownTime to Sell? - MarketBeat
BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts - Fierce Pharma
Wolfe Research reiterates Outperform on BioMarin stock at $95 By Investing.com - Investing.com India
Wolfe Research reiterates Outperform on BioMarin stock at $95 - Investing.com
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):